

# AstraZeneca

## VT S.92 (Act 193, Sec.10.18 V.S.A § 4637) Reporting

In Accordance with the requirements set forth in the VT S.92 (Act 193, Sec.10.18 V.S.A § 4637) regulation, this is a notification of AstraZeneca's intent to engage in the wholesale importation of the prescription drug, SAPHNELO™ (anifrolumab-fnia) into the state of Vermont. Product is expected to be available in the market on August 02, 2021.

### The Product and Pricing

Branded Name	Generic Name	NDC	WAC Package Price	Effective Date
SAPHNELO	anifrolumab-fnia	00310-3040-00	\$4,600.54	08/02/2021